エリキュース（アピキサバン）の市場規模、シェア、動向分析レポート：適応症別、流通チャネル別、地域別、セグメント別予測、2025-2033年

エリキュース（アピキサバン）市場サマリー

世界のエリキュース（アピキサバン）市場規模は2024年に207億米ドルと推計され、2025年から2033年までのCAGRは-2.2%で、2033年には188億7,000万米ドルに達すると予測されます。主な原因は、特許独占権の喪失、ジェネリック医薬品の競争激化、主要市場全体での価格下落です。

心房細動（AF）と静脈血栓塞栓症（VTE）の世界の負担増は、エリキュース（アピキサバン）市場の主要な促進要因として浮上しています。心房細動は脳卒中のリスクを著しく高めるため、長期的な予防を目的とした抗凝固薬の使用が増加しています。2022年6月、Journal of Clinical Medicine誌は、390万人を超える成人の心房細動患者を対象としたメタアナリシスを発表し、アピキサバンの安全性と有効性を評価しました。この研究では、アピキサバンは他の抗凝固薬と比較して良好な転帰を示し、脳卒中リスク、死亡率、大出血が低いことが明らかになりました。エリキュースはその良好な安全性プロファイルと最小限のモニタリングの必要性により、好ましい選択肢となっています。循環器科の診療ガイドラインは直接経口抗凝固薬の使用を拡大し、プライマリーケアや専門医療で広く採用されるようになりました。心房細動とVTEの症例が、特に高齢化した人々の間で増加するにつれて、エリキュースのような信頼性が高く、投与が容易な抗凝固薬に対する需要は増加の一途をたどっています。

直接経口抗凝固薬への臨床実践のシフトは、エリキュースの市場での地位を強化しています。ヘルスケアプロバイダーは、予測可能な薬物動態、固定用量、ワルファリンよりも低い大出血イベントのリスクを持つDOACを高く評価しています。エリキュースは大規模試験で優れた結果を示しており、世界的に高い処方率に貢献しています。患者は簡便な治療レジメンによってアドヒアランスが向上し、ヘルスケアへの受診回数が減るという利点があります。従来の抗凝固薬からDOACへの移行が加速する中、エリキュースは世界の抗凝固薬市場でシェアを拡大する好位置にあります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 エリキュース（アピキサバン）市場の変数、動向、範囲

• 市場系統の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析
  • 特許満了分析
  • 価格分析

第4章 エリキュース（アピキサバン）市場：適応症ビジネス分析

• 適応症市場シェア、2024年および2033年
• 適応症セグメントダッシュボード
• 市場規模、予測、動向分析（適応症別、2021～2033年）
• 心房細動（AF）
• 深部静脈血栓症（DVT）
• 肺塞栓症（PE）
• 術後静脈血栓塞栓症（VTE）予防
• その他

第5章 エリキュース（アピキサバン）市場：流通チャネルのビジネス分析

• 流通チャネル市場シェア、2024年および2033年
• 流通チャネルセグメントダッシュボード
• 市場規模と予測および動向分析（流通チャネル別、2021～2033年）
• 病院薬局
• 小売薬局
• オンライン薬局

第6章 エリキュース（アピキサバン）市場：地域推定・動向分析

• 地域別市場シェア分析、2024年および2033年
• 地域市場ダッシュボード
• 市場規模と予測動向分析、2021～2033年
• 北米
  • 国別、2021年～2033年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東およびアフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • F. Hoffmann-La Roche Ltd.
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • AstraZeneca
  • Johnson &Johnson Private Limited
  • Bristol-Myers Squibb Company

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global Eliquis (apixaban) market, by region, 2021 - 2033 (USD Million)
• Table 4 Global Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 5 Global Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 6 North America Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
• Table 7 North America Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 8 North America Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 9 U.S. Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 10 U.S. Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 11 Canada Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 12 Canada Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 13 Mexico Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 14 Mexico Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 15 Europe Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
• Table 16 Europe Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 17 Europe Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 18 UK Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 19 UK Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 20 Germany Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 21 Germany Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 22 France Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 23 France Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 24 Italy Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 25 Italy Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 26 Spain Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 27 Spain Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 28 Norway Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 29 Norway Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 30 Denmark Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 31 Denmark Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 32 Sweden Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 33 Sweden Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 34 Asia Pacific Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
• Table 35 Asia Pacific Eliquis (apixaban) market, by indication, 2021 - 2033 (USD
• Table 36 Asia Pacific Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 37 Japan Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 38 Japan Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 39 China Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 40 China Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 41 India Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 42 India Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 43 Australia Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 44 Australia Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 45 South Korea Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 46 South Korea Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 47 Thailand Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 48 Thailand Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 49 Latin America Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
• Table 50 Latin America Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 51 Latin America Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 52 Brazil Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 53 Brazil Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 54 Argentina Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 55 Argentina Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 56 Middle East & Africa Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
• Table 57 Middle East & Africa Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 58 Middle East & Africa Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 59 South Africa Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 60 South Africa Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 61 Saudi Arabia Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 62 Saudi Arabia Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 63 UAE Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 64 UAE Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
• Table 65 Kuwait Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
• Table 66 Kuwait Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Eliquis (apixaban) market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapeutic approach and application outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 Eliquis (apixaban) market dynamics
• Fig. 12 Eliquis (apixaban) market: Porter's five forces analysis
• Fig. 13 Eliquis (apixaban) market: PESTLE analysis
• Fig. 14 Indication market, 2021 - 2033 (USD Million)
• Fig. 15 Atrial Fibrillation (AF) market, 2021 - 2033 (USD Million)
• Fig. 16 Deep Vein Thrombosis (DVT) market, 2021 - 2033 (USD Million)
• Fig. 17 Pulmonary Embolism (PE) market, 2021 - 2033 (USD Million)
• Fig. 18 Post-Operative Venous Thromboembolism (VTE) Prophylaxis market, 2021 - 2033 (USD Million)
• Fig. 19 Others market, 2021 - 2033 (USD Million)
• Fig. 20 Distribution channel market, 2021 - 2033 (USD Million)
• Fig. 21 Hospital Pharmacies market, 2021 - 2033 (USD Million)
• Fig. 22 Retail Pharmacies market, 2021 - 2033 (USD Million)
• Fig. 23 Online Pharmacies market, 2021 - 2033 (USD Million)
• Fig. 24 Eliquis (apixaban) market revenue, by region
• Fig. 25 Regional marketplace: Key takeaways
• Fig. 26 North America Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 27 U.S. country dynamics
• Fig. 28 U.S. Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 29 Canada country dynamics
• Fig. 30 Canada Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 31 Mexico country dynamics
• Fig. 32 Mexico Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 33 Europe Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 34 UK country dynamics
• Fig. 35 UK Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 36 Germany country dynamics
• Fig. 37 Germany Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 38 France country dynamics
• Fig. 39 France Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 40 Italy country dynamics
• Fig. 41 Italy Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 42 Spain country dynamics
• Fig. 43 Spain Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 44 Norway country dynamics
• Fig. 45 Norway Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 46 Sweden country dynamics
• Fig. 47 Sweden Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 48 Denmark country dynamics
• Fig. 49 Denmark Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 50 Asia Pacific Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 51 Japan country dynamics
• Fig. 52 Japan Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 53 China country dynamics
• Fig. 54 China Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 55 India country dynamics
• Fig. 56 India Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 57 Australia country dynamics
• Fig. 58 Australia Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 59 South Korea country dynamics
• Fig. 60 South Korea Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 61 Thailand country dynamics
• Fig. 62 Thailand Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 63 Latin America Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 64 Brazil country dynamics
• Fig. 65 Brazil Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 66 Argentina country dynamics
• Fig. 67 Argentina Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 68 MEA Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 69 South Africa country dynamics
• Fig. 70 South Africa Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 71 Saudi Arabia country dynamics
• Fig. 72 Saudi Arabia Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 73 UAE country dynamics
• Fig. 74 UAE Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 75 Kuwait country dynamics
• Fig. 76 Kuwait Eliquis (apixaban) market, 2021 - 2033 (USD Million)
• Fig. 77 Company categorization
• Fig. 78 Company market position analysis
• Fig. 79 Strategic framework

Eliquis (Apixaban) Market Summary

The global Eliquis (apixaban) market size was estimated at USD 20.70 billion in 2024 and is projected to reach USD 18.87 billion by 2033, with a decline of CAGR of -2.2% from 2025 to 2033, primarily due to loss of patent exclusivity, growing generic competition, and consequent price erosion across major markets.

The increasing global burden of atrial fibrillation (AF) and venous thromboembolism (VTE) has emerged as a major driver for the Eliquis (Apixaban) market. AF significantly raises the risk of stroke, prompting greater use of anticoagulants for long-term prevention. In June 2022, the Journal of Clinical Medicine published a meta-analysis of over 3.9 million adults with atrial fibrillation, assessing apixaban's safety and effectiveness. The study found that apixaban had favorable outcomes compared to other anticoagulants, with lower stroke risks, mortality, and major bleeding. Eliquis has become a preferred option due to its favorable safety profile and minimal need for monitoring. Clinical guidelines in cardiology have expanded the use of direct oral anticoagulants, leading to broader adoption across primary and specialty care. As AF and VTE cases rise, particularly among aging populations, the demand for reliable and easy-to-administer anticoagulants such as Eliquis continues to grow.

Shifts in clinical practice toward direct oral anticoagulants have strengthened Eliquis's market position. Healthcare providers value DOACs for their predictable pharmacokinetics, fixed dosing, and lower risk of major bleeding events than warfarin. Eliquis has shown superior results in large-scale trials, contributing to its high prescription rates worldwide. Patients benefit from simplified treatment regimens that improve adherence and reduce healthcare visits. As transitioning from traditional anticoagulants to DOACs accelerates, Eliquis is well-positioned to capture a growing share of the global anticoagulant market.

Global Eliquis (Apixaban) Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Eliquis (apixaban) market report based on indication, distribution channel, and region:

• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Atrial Fibrillation (AF)
• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Post-Operative Venous Thromboembolism (VTE) Prophylaxis
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Eliquis (Apixaban) Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Eliquis (Apixaban) Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2033
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
• 4.4. Atrial Fibrillation (AF)
  • 4.4.1. Atrial Fibrillation (AF) Market, 2021 - 2033 (USD Million)
• 4.5. Deep Vein Thrombosis (DVT)
  • 4.5.1. Deep Vein Thrombosis (DVT) Market, 2021 - 2033 (USD Million)
• 4.6. Pulmonary Embolism (PE)
  • 4.6.1. Pulmonary Embolism (PE) Market, 2021 - 2033 (USD Million)
• 4.7. Post-Operative Venous Thromboembolism (VTE) Prophylaxis
  • 4.7.1. Post-Operative Venous Thromboembolism (VTE) Prophylaxis Market, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Eliquis (Apixaban) Market: Distribution Channel Business Analysis

• 5.1. Distribution Channel Market Share, 2024 & 2033
• 5.2. Distribution Channel Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
• 5.4. Hospital Pharmacies
  • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
• 5.5. Retail Pharmacies
  • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
• 5.6. Online Pharmacies
  • 5.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 6. Eliquis (Apixaban) Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 6.4. North America
  • 6.4.1. North America Eliquis (Apixaban) Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Distribution Channel Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. U.S. Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Distribution Channel Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. U.S. Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Distribution Channel Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. Mexico Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Distribution Channel Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. UK Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Distribution Channel Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. Germany Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Distribution Channel Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. France Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Distribution Channel Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Italy Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Distribution Channel Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. Spain Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Distribution Channel Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Denmark Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Distribution Channel Disease Prevalence
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Framework
    • 6.5.8.5. Sweden Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Distribution Channel Disease Prevalence
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Framework
    • 6.5.9.5. Norway Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Distribution Channel Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Distribution Channel Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Distribution Channel Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. India Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Distribution Channel Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Australia Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Distribution Channel Disease Prevalence
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Framework
    • 6.6.6.5. South Korea Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Distribution Channel Disease Prevalence
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Framework
    • 6.6.7.5. Thailand Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Distribution Channel Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. Japan Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Distribution Channel Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. China Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Distribution Channel Disease Prevalence
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Framework
    • 6.8.2.5. South Africa Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Distribution Channel Disease Prevalence
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Framework
    • 6.8.3.5. Saudi Arabia Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Distribution Channel Disease Prevalence
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Framework
    • 6.8.4.5. UAE Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Distribution Channel Disease Prevalence
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Framework
    • 6.8.5.5. Kuwait Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. F. Hoffmann-La Roche Ltd.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Mylan NV
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Teva Pharmaceutical Industries Ltd.
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Sanofi
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Pfizer Inc.
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. GSK plc
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Novartis AG
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. AstraZeneca
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Johnson & Johnson Private Limited
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Bristol-Myers Squibb Company
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives